Skip to main content
Peter Mohr, MD, Cardiology, Sacramento, CA

PeterJacobMohrMD

Cardiology Sacramento, CA

Adult Congenital Heart Disease, Interventional Cardiology

Physician

Dr. Mohr is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Mohr's full profile

Already have an account?

  • Office

    6600 Bruceville Rd
    Mob 3; 1st Floor
    Sacramento, CA 95823
    Phone+1 916-688-2315
    Fax+1 314-362-4278

Education & Training

  • Scripps Clinic/Scripps Green Hospital
    Scripps Clinic/Scripps Green HospitalFellowship, Interventional Cardiology, 2010 - 2011
  • SSM Health/Saint Louis University School of Medicine
    SSM Health/Saint Louis University School of MedicineFellowship, Cardiovascular Disease, 2007 - 2010
  • Washington University/B-JH/SLCH Consortium
    Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2003 - 2006
  • Tufts University School of Medicine
    Tufts University School of MedicineClass of 2003

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2010 - 2026
  • American Board of Internal Medicine Cardiovascular Disease
  • American Board of Internal Medicine Interventional Cardiology
  • National Board of Physicians and Surgeons Cardiovascular Disease
  • National Board of Physicians and Surgeons Interventional Cardiology

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Bristol Myers Squibb Receives European Commission Approval for Opdivo (Nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
    Bristol Myers Squibb Receives European Commission Approval for Opdivo (Nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC MelanomaAugust 23rd, 2023

Professional Memberships